{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:33:58Z","timestamp":1793370838942,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00115-020-01051-3","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T11:09:16Z","timestamp":1611745756000},"page":"433-440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pharmakotherapie von Angsterkrankungen\u00a0\u2013 leitliniengerechte Therapie und Neuentwicklungen","Pharmacotherapy of anxiety disorders\u2014Guideline-conform treatment and new developments"],"prefix":"10.1007","volume":"92","author":[{"given":"P.","family":"Zwanzger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Singewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bandelow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,27]]},"reference":[{"key":"1051_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1017\/S1461145705006358","volume":"10","author":"DS Baldwin","year":"2007","unstructured":"Baldwin\u00a0DS, Montgomery\u00a0SA, Nil\u00a0R, Lader\u00a0M (2007) Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 10:73\u201384","journal-title":"Int J Neuropsychopharmacol"},{"key":"1051_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1080\/15622975.2016.1190867","volume":"18","author":"B Bandelow","year":"2016","unstructured":"Bandelow\u00a0B, Baldwin\u00a0D, Abelli\u00a0M, Bolea-Alamanac\u00a0B, Bourin\u00a0M, Chamberlain\u00a0SR, Cinosi\u00a0E, Davies\u00a0S, Domschke\u00a0K, Fineberg\u00a0N, Gr\u00fcnblatt\u00a0E, Jarema\u00a0M, Kim\u00a0YK, Maron\u00a0E, Masdrakis\u00a0V, Mikova\u00a0O, Nutt\u00a0D, Pallanti\u00a0S, Pini\u00a0S, Str\u00f6hle\u00a0A, Thibaut\u00a0F, Vaghi\u00a0MM, Won\u00a0E, Wedekind\u00a0D, Wichniak\u00a0A, Woolley\u00a0J, Zwanzger\u00a0P, Riederer\u00a0P (2016) Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: neurochemistry, neurophysiology and neurocognition. World J Biol Psychiatry 18:162\u2013214","journal-title":"World J Biol Psychiatry"},{"key":"1051_CR3","unstructured":"Bandelow B, Wiltink J, Alpers GW, Benecke C, Deckert J, Eckhardt-Henn A, Ehrig C, Engel E, Falkai P, Geiser F, Gerlach AL, Harfst T, Hau S, Joraschky P, Kellner M, K\u00f6llner V, Kopp I, Langs G, Lichte T, Liebeck H, Matzat J, Reitt M, R\u00fcddel HP, Rudolf S, Schick G, Schweiger U, Simon R, Springer A, Staats H, Str\u00f6hle A, Str\u00f6hm W, Waldherr B, Watzke B, Wedekind D, Zottl C, Zwanzger P, Beutel ME (2014) S3-Leitlinie Behandlung von Angstst\u00f6rungen. http:\/\/www.awmf.org\/leitlinien\/detail\/II\/051-028 (Stand: 15.04.2014 (Revision in \u00dcberarbeitung)). Zugegriffen: 15.10.2020"},{"key":"1051_CR4","volume-title":"Anxiety disorders. Advances in experimental medicine and biology","author":"B Bandelow","year":"2020","unstructured":"Bandelow\u00a0B (2020) Current and novel psychopharmacological drugs for anxiety disorders. In: Kim\u00a0YK (Hrsg) Anxiety disorders. Advances in experimental medicine and biology, Bd. 1191. Springer, Singapore"},{"key":"1051_CR5","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","volume":"6","author":"N Black","year":"2019","unstructured":"Black\u00a0N, Stockings\u00a0E, Campbell\u00a0G, Tran\u00a0LT, Zagic\u00a0D, Hall\u00a0WD, Farrell\u00a0M, Degenhardt\u00a0L (2019) Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a\u00a0systematic review and meta-analysis. Lancet Psychiatry 6:995\u20131010","journal-title":"Lancet Psychiatry"},{"key":"1051_CR6","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.euroneuro.2017.08.430","volume":"27","author":"U Bonnet","year":"2017","unstructured":"Bonnet\u00a0U, Scherbaum\u00a0N (2017) How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol 27:1185\u20131215","journal-title":"Eur Neuropsychopharmacol"},{"key":"1051_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3390\/brainsci9070164","volume":"9","author":"JK Carpenter","year":"2019","unstructured":"Carpenter\u00a0JK, Pinaire\u00a0M, Hofmann\u00a0SG (2019) From extinction learning to anxiety treatment: mind the gap. Brain Sci 9:164","journal-title":"Brain Sci"},{"key":"1051_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0269881110379283","volume":"25","author":"JA Crippa","year":"2011","unstructured":"Crippa\u00a0JA, Derenusson\u00a0GN, Ferrari\u00a0TB, Wichert-Ana\u00a0L, Duran\u00a0FL, Martin-Santos\u00a0R, Sim\u00f5es\u00a0MV, Bhattacharyya\u00a0S, Fusar-Poli\u00a0P, Atakan\u00a0Z, Filho\u00a0SA, Freitas-Ferrari\u00a0MC, McGuire\u00a0PK, Zuardi\u00a0AW, Busatto\u00a0GF, Hallak\u00a0JE (2011) Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a\u00a0preliminary report. J\u00a0Psychopharmacol 25:121\u2013130","journal-title":"J Psychopharmacol"},{"key":"1051_CR9","first-page":"19com12794","volume":"80","author":"G Fava","year":"2019","unstructured":"Fava\u00a0G, Cosci\u00a0F (2019) Understanding and managing withdrawal syndromes after discontinuation of antidepressant drugs. J\u00a0Clin Psychiatry 80:19com12794","journal-title":"J Clin Psychiatry"},{"key":"1051_CR10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1080\/10715762.2018.1475733","volume":"52","author":"ADG Fedoce","year":"2018","unstructured":"Fedoce\u00a0ADG, Ferreira\u00a0F, Bota\u00a0RG, Bonet-Costa\u00a0V, Sun\u00a0PY, Davies\u00a0KJA (2018) The role of oxidative stress in anxiety disorder: cause or consequence? Free Radic Res 52:737\u2013750","journal-title":"Free Radic Res"},{"key":"1051_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.coph.2018.02.004","volume":"38","author":"F Ferraguti","year":"2018","unstructured":"Ferraguti\u00a0F (2018) Metabotropic glutamate receptors as targets for novel anxiolytics. Curr Opin Pharmacol 38:37\u201342","journal-title":"Curr Opin Pharmacol"},{"key":"1051_CR12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/0269881119874457","volume":"34","author":"P Glue","year":"2020","unstructured":"Glue\u00a0P, Neehoff\u00a0S, Sabadel\u00a0A, Broughton\u00a0L, Le Nedelec\u00a0M, Shadli\u00a0S, McNaughton\u00a0N, Medlicott\u00a0NJ (2020) Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: exploratory double-blind psychoactive-controlled replication study. J\u00a0Psychopharmacol 34:267\u2013272","journal-title":"J Psychopharmacol"},{"key":"1051_CR13","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nrd4075","volume":"12","author":"G Griebel","year":"2013","unstructured":"Griebel\u00a0G, Holmes\u00a0A (2013) 50\u00a0years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov 12:667\u2013687","journal-title":"Nat Rev Drug Discov"},{"key":"1051_CR14","doi-asserted-by":"publisher","first-page":"574","DOI":"10.2174\/1570159X15666170913110426","volume":"16","author":"YK Kim","year":"2018","unstructured":"Kim\u00a0YK, Jeon\u00a0SW (2018) Neuroinflammation and the immune-kynurenine pathway in anxiety disorders. Curr Neuropharmacol 16:574\u2013582","journal-title":"Curr Neuropharmacol"},{"key":"1051_CR15","series-title":"AMER PSYCHOLOGICAL ASSN","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1037\/0000150-019","volume-title":"Clinical handbook of fear and anxiety: Maintenance processes and treatment mechanisms","author":"V La Buissonni\u00e8re-Ariza","year":"2020","unstructured":"La Buissonni\u00e8re-Ariza\u00a0V, Schneider\u00a0SC, Storch\u00a0EA (2020) Pharmacological enhancement of extinction learning. In: Abramowitz\u00a0JS, Blakey\u00a0SM (Hrsg) Clinical handbook of fear and anxiety: Maintenance processes and treatment mechanisms. AMER PSYCHOLOGICAL ASSN, S\u00a0345\u2013357"},{"key":"1051_CR16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s13311-017-0585-0","volume":"15","author":"G Lach","year":"2018","unstructured":"Lach\u00a0G, Schellekens\u00a0H, Dinan\u00a0TG, Cryan\u00a0JF (2018) Anxiety, depression, and the microbiome: a role for gut peptides. Neurotherapeutics 15:36\u201359","journal-title":"Neurotherapeutics"},{"key":"1051_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.pharmthera.2019.01.002","volume":"197","author":"VM Lauschke","year":"2019","unstructured":"Lauschke\u00a0VM, Zhou\u00a0Y, Ingelman-Sundberg\u00a0M (2019) Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. Pharmacol Ther 197:122\u2013152","journal-title":"Pharmacol Ther"},{"key":"1051_CR18","first-page":"171","volume":"27","author":"LJ Mertens","year":"2020","unstructured":"Mertens\u00a0LJ, Gr\u00fcnder\u00a0G (2020) Klassische Psychedelika als Therapeutika in der Psychiatrie. Psychopharmakotherapie 27:171\u2013180","journal-title":"Psychopharmakotherapie"},{"key":"1051_CR19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.euroneuro.2015.01.016","volume":"25","author":"MJ Millan","year":"2015","unstructured":"Millan\u00a0MJ, Goodwin\u00a0GM, Meyer-Lindenberg\u00a0A, Ogren\u00a0OS (2015) Learning from the past and looking to the future: emerging perspectives for improving the treatment of psychiatric disorders. Eur Neuropsychopharmacol 25:599\u2013656","journal-title":"Eur Neuropsychopharmacol"},{"key":"1051_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/00004714-200102000-00011","volume":"21","author":"HJ M\u00f6ller","year":"2001","unstructured":"M\u00f6ller\u00a0HJ, Volz\u00a0HP, Reimann\u00a0IW, Stoll\u00a0KD (2001) Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J\u00a0Clin Psychopharmacol 21:59\u201365","journal-title":"J Clin Psychopharmacol"},{"key":"1051_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00406-017-0852-4","volume":"269","author":"HJ M\u00f6ller","year":"2019","unstructured":"M\u00f6ller\u00a0HJ, Volz\u00a0HP, Dienel\u00a0A, Schl\u00e4fke\u00a0S, Kasper\u00a0S (2019) Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials. Eur Arch Psychiatry Clin Neurosci 269:183\u2013193","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1051_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/01.yic.0000137184.64610.c8","volume":"19","author":"SA Montgomery","year":"2004","unstructured":"Montgomery\u00a0SA, Kennedy\u00a0SH, Burrows\u00a0GD, Lejoyeux\u00a0M, Hindmarch\u00a0I (2004) Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a\u00a0randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 19:271\u2013280","journal-title":"Int Clin Psychopharmacol"},{"key":"1051_CR23","first-page":"185","volume":"42","author":"CP Murphy","year":"2019","unstructured":"Murphy\u00a0CP, Singewald\u00a0N (2019) Role of microRNAs in anxiety and anxiety-related disorders. Curr Top Behav Neurosci 42:185\u2013219","journal-title":"Curr Top Behav Neurosci"},{"key":"1051_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/acps.12784","volume":"136","author":"J N\u00e4slund","year":"2017","unstructured":"N\u00e4slund\u00a0J, Hieronymus\u00a0F, Emilsson\u00a0JF, Lisinski\u00a0A, Nilsson\u00a0S, Eriksson\u00a0E (2017) Incidence of early anxiety aggravation in trials of selective serotonin reuptake inhibitors in depression. Acta Psychiatr Scand 136:343\u2013351","journal-title":"Acta Psychiatr Scand"},{"key":"1051_CR25","doi-asserted-by":"publisher","first-page":"239821281880403","DOI":"10.1177\/2398212818804030","volume":"2","author":"JR Nicholson","year":"2018","unstructured":"Nicholson\u00a0JR, Sommer\u00a0B (2018) The research domain criteria framework in drug discovery for neuropsychiatric diseases: focus on negative valence. Brain Neurosci Adv 2:2398212818804030","journal-title":"Brain Neurosci Adv"},{"key":"1051_CR26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/JCP.0000000000001021","volume":"39","author":"RW Pies","year":"2019","unstructured":"Pies\u00a0RW (2019) Antidepressant discontinuation\u2014a tale of two narratives. J\u00a0Clin Psychopharmacol 39:185\u2013188","journal-title":"J Clin Psychopharmacol"},{"key":"1051_CR27","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1176\/appi.ajp.2020.20010055","volume":"177","author":"KJ Ressler","year":"2020","unstructured":"Ressler\u00a0KJ (2020) Translating across circuits and genetics toward progress in fear- and anxiety-related disorders. Am J Psychiatry 177:214\u2013222","journal-title":"Am J Psychiatry"},{"key":"1051_CR28","doi-asserted-by":"publisher","first-page":"107402","DOI":"10.1016\/j.pharmthera.2019.107402","volume":"204","author":"SB Sartori","year":"2019","unstructured":"Sartori\u00a0SB, Singewald\u00a0N (2019) Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacol Ther 204:107402","journal-title":"Pharmacol Ther"},{"key":"1051_CR29","doi-asserted-by":"publisher","first-page":"101830","DOI":"10.1016\/j.cpr.2020.101830","volume":"77","author":"MA Schiele","year":"2020","unstructured":"Schiele\u00a0MA, Gottschalk\u00a0MG, Domschke\u00a0K (2020) The applied implications of epigenetics in anxiety, affective and stress-related disorders\u2014a review and synthesis on psychosocial stress, psychotherapy and prevention. Clin Psychol Rev 77:101830","journal-title":"Clin Psychol Rev"},{"key":"1051_CR30","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.pharmthera.2014.12.004","volume":"149","author":"N Singewald","year":"2015","unstructured":"Singewald\u00a0N, Schmuckermair\u00a0C, Whittle\u00a0N, Holmes\u00a0A, Ressler\u00a0KJ (2015) Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacol Ther 149:150\u2013190","journal-title":"Pharmacol Ther"},{"key":"1051_CR31","first-page":"30","volume":"84","author":"P Zwanzger","year":"2016","unstructured":"Zwanzger\u00a0P (2016) Pharmakotherapie bei Angsterkrankungen. Fortschr Neurol Psychiatr 84:30\u2013314","journal-title":"Fortschr Neurol Psychiatr"},{"key":"1051_CR32","first-page":"185","volume-title":"Angst \u2013 Medizin. Psychologie. Gesellschaft","author":"P Zwanzger","year":"2019","unstructured":"Zwanzger\u00a0P (2019) Pharmakotherapie. In: Zwanzger\u00a0P (Hrsg) Angst \u2013 Medizin. Psychologie. Gesellschaft. MVV, Berlin, S\u00a0185\u2013196"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-020-01051-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-020-01051-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-020-01051-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T09:06:34Z","timestamp":1619773594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-020-01051-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,27]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1051"],"URL":"https:\/\/doi.org\/10.1007\/s00115-020-01051-3","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,27]]},"assertion":[{"value":"11 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"P.\u00a0Zwanzger hat in den letzten 36\u00a0Monaten Vortr\u00e4ge f\u00fcr Janssen-Cilag, Schwabe und Pfizer gehalten und ist Mitglied im Advisory Board von Esketamin, Janssen-Cilag. B.\u00a0Bandelow war in den letzten 36 Monaten Mitglied im Speakers Board von Cannaxan, Janssen, Lilly, Pfizer und Schwabe sowie im Advisory Board von Lundbeck und Pfizer. N.\u00a0Singewald gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}